Watch LIMNW. Know when insiders buy.
One email the day a filing lands. Free.
LIMNW
Liminatus Pharma, Inc.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$12.5MNET CASH —52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$1.4M | −$1.4M | −1342.2% | -0.03 | −$970K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$1.1M | −$1.1M | — | -0.03 | −$2M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$884K | −$8.2M | — | -0.34 | −$387K | $0 | −$387K | Mar 31 |
| Q3 2025 · Sep 30 | — | — | — | −$701K | −$1.8M | — | -0.07 | −$601K | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$1.1M | $113K | — | 0.00 | −$8.8M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$264K | −$328K | — | -0.02 | −$159K | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$167K | −$230K | — | -0.01 | −$141K | — | — | Mar 31 |
| Q3 2024 · Sep 30 | — | — | — | −$543K | −$601K | — | -0.03 | −$206K | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$909K | −$961K | — | -0.05 | −$1.1M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$247 | −$1.8M | — | -2.47 | $0 | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$3M | −$10.2M | — | -0.43 | −$10M | $13K | −$10M | — | — |
| FY2024 · to Dec 31 | — | — | −$3.3M | −$3.5M | — | -0.20 | −$1.5M | — | — | — | — |
Every number comes from Liminatus Pharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.